Biocon Gets Regulatory Nod To Use Drug Itolizumab On COVID-19 Patients

News: Biocon drug Itolizumab has been approved by the Drugs Controller General of India(DCGI) for treating moderate to severe Covid-19 patients. Facts: Itolizumab: It is a monoclonal antibody drug manufactured by Biocon for the treatment of severe chronic plaque psoriasis.  Monoclonal antibodies are lab-made proteins that act like human antibodies in the immune system and… Continue reading Biocon Gets Regulatory Nod To Use Drug Itolizumab On COVID-19 Patients

Blog
Academy
Community